Passage Bio to Present Positive Interim Data from Cohort 1 - GlobeNewswire
Dose 1 of PBFT02 in upliFT-D trial achieved robust CSF progranulin levels in FTD-GRN patients, sustained for up to 12 months, and was well-tolerated with no serious adverse events.
Related Clinical Trials
Reference News
Passage Bio to Present Positive Interim Data from Cohort 1 - GlobeNewswire
Dose 1 of PBFT02 in upliFT-D trial achieved robust CSF progranulin levels in FTD-GRN patients, sustained for up to 12 months, and was well-tolerated with no serious adverse events.